Merck’s Keytruda sales eclipse $18B on the year, while numbers for Lagevrio surprise

Merck’s blockbuster cancer drug Keytruda made $18.4 billion in the first nine months of the year — nearly the same amount as the reported revenue of the NFL in 2022.

Caroline Litchfield

In the third quarter of 2023, Merck reported $6.3…
Click here to view original post